Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $900,900.00 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 30,000 shares of the business’s stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $30.03, for a total transaction of $900,900.00. Following the transaction, the insider owned 195,825 shares in the company, valued at approximately $5,880,624.75. This represents a 13.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kestra Medical Technologies Stock Up 2.5%

Shares of NASDAQ:KMTS traded up $0.74 during midday trading on Thursday, hitting $30.61. 470,598 shares of the stock were exchanged, compared to its average volume of 351,886. The company has a market capitalization of $1.82 billion, a PE ratio of -11.46 and a beta of 0.51. Kestra Medical Technologies, Ltd. has a 52-week low of $17.34 and a 52-week high of $31.04. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.69 and a current ratio of 4.69. The business’s fifty day simple moving average is $26.59 and its two-hundred day simple moving average is $23.76.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). The firm had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. As a group, research analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KMTS has been the topic of a number of recent research reports. BTIG Research restated a “buy” rating and set a $32.00 price target on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating on the stock. Piper Sandler reissued an “overweight” rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Weiss Ratings upgraded Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. Finally, Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KMTS. Sterling Capital Management LLC boosted its position in shares of Kestra Medical Technologies by 834.0% in the third quarter. Sterling Capital Management LLC now owns 878 shares of the company’s stock valued at $25,000 after acquiring an additional 784 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in Kestra Medical Technologies during the 3rd quarter valued at $353,000. Quantinno Capital Management LP acquired a new position in Kestra Medical Technologies during the 1st quarter valued at $431,000. California State Teachers Retirement System boosted its holdings in Kestra Medical Technologies by 39.2% in the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock valued at $555,000 after purchasing an additional 7,844 shares during the period. Finally, Spartan Wealth Advisory Services LLC acquired a new stake in Kestra Medical Technologies in the 1st quarter worth $603,000.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.